Factors associated with knowledge and vaccination intention for human papillomavirus on trans girls by their main caregiver: A cross-sectional study.
HPV knowledge
adolescents
human papilloma virus - HPV
main caregiver
transwomen
vaccination intention
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
11
2022
accepted:
16
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Trans women are highly affected by the human papillomavirus (HPV) and are at risk of suffering from HPV-related diseases such as oropharyngeal, anal, penile, or neovaginal neoplasia. HPV vaccination seems to be a good strategy to reduce HPV-related diseases, mainly during the early age before the first sexual intercourse, but only cisgender girls are covered by the National Health Services, while some high-risk groups such as trans girls are not included. Achieving a high vaccination rate is important in the adolescent population, but there are many factors that could affect it, such as lack of knowledge about HPV or fear of side effects by patients and main caregivers. The aim of our study is to analyze the knowledge of trans girls' main caregivers about HPV-related diseases in the general population and, in particular, in trans women, as well as factors associated with HPV vaccination intention. A cross-sectional study was performed with the collaboration of main caregivers of adolescent trans girls, between 9 and 16 years old, assisted in two reference centers' multidisciplinary Gender Diversity Units. Information was requested through a self-completed questionnaire: HPV-related diseases Knowledge Transwomen questionnaire (HPV-TQ) was elaborated based on a 19-item self-administered questionnaire and score was standardized from 0 to 19 points. Percentage of correct answers was calculated and defined by the group of high scores that showed over 70% correct answers. A total of 65 main caregivers were included. Almost all main caregivers were mothers with a Caucasian ethnicity. The HPV-TQ average score was 11 (3.7) with an average correct answer of 58.1% (19.6). Only 17/65 (26.1%) of main caregivers were highly knowledgeable in HPV. Of 65 trans girls, 14 were already vaccinated (29.8% of trans girls over 12 years old); 78.5% were not vaccinated and only 21.5% had intentions to be vaccinated. The group with a high score in HPV-TQ had a longer follow-up at the transgender unit, a higher maternal vaccination rate, and a positive family history of HPV-related disease, especially in mothers. Adolescent trans girls attended to in our units had a low rate and a low intention of vaccination against HPV. Education on and promotion and prevention of transgender HPV-related diseases should probably be implemented to achieve a higher knowledge and vaccination coverage in adolescent trans girls.
Identifiants
pubmed: 37063882
doi: 10.3389/fimmu.2023.1097449
pmc: PMC10098167
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1097449Informations de copyright
Copyright © 2023 Domínguez-Riscart, Ariza-Jimenez, Baez-Castillo and Mateo-Gavira.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sex Transm Infect. 2018 May;94(3):191
pubmed: 29764977
Front Public Health. 2022 May 10;10:729497
pubmed: 35619814
Health Promot Pract. 2019 Mar;20(2):173-187
pubmed: 29947564
Case Rep Obstet Gynecol. 2019 Jan 16;2019:4820396
pubmed: 30775041
PLoS One. 2018 Apr 11;13(4):e0195801
pubmed: 29641563
Hum Vaccin Immunother. 2021 Dec 2;17(12):5407-5412
pubmed: 35213950
An Sist Sanit Navar. 2018 Apr 30;41(1):27-34
pubmed: 29358785
Ups J Med Sci. 2013 Nov;118(4):263-70
pubmed: 23777602
Hum Vaccin Immunother. 2022 Dec 31;18(1):2016007
pubmed: 35294325
Sex Transm Dis. 2017 Jul;44(7):436-441
pubmed: 28608795
J Low Genit Tract Dis. 2014 Apr;18(2):E43-5
pubmed: 23994948
J Community Health. 2012 Dec;37(6):1157-63
pubmed: 22968822
Front Pharmacol. 2021 Mar 24;12:600273
pubmed: 33867977
JAMA Otolaryngol Head Neck Surg. 2017 Feb 1;143(2):117-124
pubmed: 27711922
Int J STD AIDS. 2018 Mar;29(3):306-308
pubmed: 28853678
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
J Am Med Inform Assoc. 2022 Jan 12;29(2):285-295
pubmed: 34383916
Vaccines (Basel). 2021 Nov 30;9(12):
pubmed: 34960159
World J Urol. 2015 Jun;33(6):873-80
pubmed: 25179010
BMC Public Health. 2022 Jun 14;22(1):1188
pubmed: 35701791
Sex Transm Dis. 2019 Oct;46(10):657-662
pubmed: 31517805
Vaccines (Basel). 2019 Sep 26;7(4):
pubmed: 31561629
J Health Psychol. 2011 Nov;16(8):1198-207
pubmed: 21558104
Papillomavirus Res. 2017 Jun;3:121-125
pubmed: 28720445
Br J Plast Surg. 2002 Jul;55(5):449-51
pubmed: 12372381
Case Rep Oncol. 2020 Jan 20;13(1):17-22
pubmed: 32110215
Transgend Health. 2016 May 01;1(1):94-98
pubmed: 29159301
Front Immunol. 2022 Jan 27;12:805695
pubmed: 35154080
BMC Public Health. 2021 Jul 28;21(1):1476
pubmed: 34320959
Sex Transm Dis. 2014 Nov;41(11):660-4
pubmed: 25299412
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915976
J Int AIDS Soc. 2021 Mar;24(3):e25691
pubmed: 33773075